initial public offerings (IPOs) trading on American exchanges

Sunday, January 25, 2015

Nevro (NVRO) began trading on the NASDAQ on 6 November 2014


Nevro Corp. is a medical device company focused on developing solutions in the neuromodulation space. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. The Company’s High-frequency spinal cord stimulation (SCS) system, the HF10 SCS, is a spinal cord simulation therapy, which provides electric pulses at a rate of approximately 10,000 Hz for spinal cord stimulation in the treatment of chronic back and leg pain. The electrical pulses are conveyed by small electrodes placed in the epidural space and connected to a battery-powered generator implanted under the skin. The Nevro Senza SCS system is available in Europe and Australia. It is undergoing a pivotal clinical trial, which is intended to collect data to support an application for a Nevro Senza implantable spinal cord stimulation system. The Company’s SENZA-RCT study is intended to evaluate the safety and effectiveness of the Senza SCS system.


4040 Campbell Ave Ste 210
MENLO PARK, CA 94025-1053
United States 

Key stats and ratios

Q3 (Sep '14)2013
Net profit margin-90.97%-110.70%
Operating margin-74.97%-107.03%
EBITD margin--106.83%
Return on average assets-53.15%-41.78%
Return on average equity--

No comments:

Post a Comment